Reduction of Myocardial Infarct Size by Dronedarone in Pigs—A Pleiotropic Action? by Skyschally, Andreas & Heusch, Gerd
SHORT COMMUNICATION
Reduction of Myocardial Infarct Size by Dronedarone
in Pigs—A Pleiotropic Action?
Andreas Skyschally & Gerd Heusch
Published online: 5 May 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Purpose Dronedarone is a first-line drug to prevent the
recurrence of atrial fibrillation according to ESC guidelines.
In the recent ATHENA trial, dronedarone reduced mortality
and also hospitalization for acute coronary syndrome in
patients with atrial fibrillation. This beneficial effect
suggests that dronedarone might have also an impact on
events associated with ischemia/reperfusion injury.
Methods Fourteen anesthetized pigs received either drone-
darone (2.5 mg/kg) or placebo. Effects of dronedarone on
heart rate and blood pressure were reversed by atrial pacing
and aortic constriction before pigs were subjected to 90 min
regional low-flow myocardial ischemia and 2 h reperfusion.
Regional myocardial blood flow was measured with micro-
spheres and infarct size determined by TTC staining.
Results With comparable heart rate and left ventricular
pressure during ischemia, dronedarone reduced infarct size
from 34±3% to 22±4% (p<0.05) of the area at risk.
Subendocardial blood flow during ischemia was not
different between groups. The relationship between ische-
mic subendocardial blood flow in the area at risk and
infarct size was displaced downwards, reflecting a direct
cardioprotective action of dronedarone.
Conclusion The beneficial effect of dronedarone is attrib-
uted to cardioprotective properties, possibly through atten-
uation of calcium overload during myocardial ischemia/
reperfusion.
Key words Dronedarone.Infarct size.Myocardial
ischemia.Reperfusion
Introduction
Atrial fibrillation is the most frequent type of cardiac
arrhythmia, with an increasing prevalence in elderly
patients. Atrial fibrillation is associated with increased
mortality, risk of stroke, and impaired quality of life.
According to the recent ESC guidelines for the manage-
ment of atrial fibrillation, dronedrone is a first-line drug to
prevent the recurrence of atrial fibrillation [1].
The electrophysiological properties of dronedarone are
similar to those of amiodarone, but dronedarone is free of
iodine and less toxic. Dronedarone acts on several ion
channels in the cardiomyocyte sarcolemma, and it is used to
inhibit the repolarizing potassium current [2]. In contrast to
amiodarone, dronedarone exerts no effect on the sodium-
potassium-ATPase, but inhibits the sodium-calcium-
exchanger [3].
In the ATHENA trial, dronedarone reduced the incidence
of cardiovascular death from 3.9% to 2.7% in patients with
atrial fibrillation and additional risk factors [4]. This
beneficial outcome in terms of mortality, notably also in
hospitalization for acute coronary syndromes, distinguishes
dronedarone from other anti-arrhythmic agents and sug-
gests a potential impact on events associated with ischemia/
reperfusion injury.
An interaction between atrial fibrillation and ischemic
heart disease is established. Myocardial ischemia per se
increases excitability and decreases conduction velocity.
The ischemia-induced loss of contractile function and
myocardial stretch add to increased excitability and slowed
conduction, and the loss of viable atrial tissue with
replacement by fibrosis further decreases conduction
velocity. Vice versa, atrial fibrillation promotes myocardial
ischemia. Apart from tachycardia which increases myocar-
dial oxygen consumption and decreases diastolic duration
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DOI 10.1007/s10557-011-6300-1[5], atrial fibrillation increases cardiac catecholamine
release and induces α-adrenergic coronary vasoconstriction
[6]. In the presence of a coronary stenosis, the α-adrenergic
coronary vasoconstriction secondary to atrial fibrillation
further decreases coronary blood flow and augments
myocardial ischemia [7, 8]. Part of the beneficial effect of
dronedarone might therefore be related to its ability to
attenuate α-adrenoceptor responses to catecholamines [9].
It is entirely unclear at present whether or not dronedar-
one, apart from its potential effects on coronary blood flow,
has direct cardioprotective properties in the setting of
myocardial ischemia/reperfusion. A potential infarct size
reduction by dronedarone might thus be secondary to a)
heart rate reduction [10], b) coronary vasodilation [11] and/
or c) an intrinsic cardioprotective property of dronedarone.
We havetherefore now tested the impact of dronedarone on
myocardial infarct size as the endpoint of protection in a
clinically relevant model of controlled myocardial ischemia
and reperfusion in anesthetized pigs [12], which permits
control of heart rate, blood pressure, and coronary blood flow.
Methods
The experimental protocols were approved by the Bioeth-
ical Committee of the district of Düsseldorf (G 1136/10).
Experimental preparation
The experimental preparation has been described in detail
recently [12]. In brief, fourteen Göttinger minipigs (20–
40 kg) were sedated with ketamine and anesthetized with
thiopental (500 mg i.v.). Anesthesia was then maintained
using enflurane (1–1.5%) with an oxygen/nitrous oxide
mixture (40%:60%). The common carotid arteries were
cannulated to measure arterial pressure and to supply blood
to an extracorporeal perfusion circuit. The jugular veins
were cannulated for volume replacement. After a left lateral
thoracotomy the heart was exposed and instrumented with a
micromanometer (P7, Konigsberg Instr., Pasadena, CA,
USA) placed in the left ventricle. A fabric band was placed
around the descending thoracic aorta to control left
ventricular peak pressure by aortic constriction. Pigs were
anticoagulated with 20,000 IU sodium heparin and addi-
tional doses of 10,000 IU at 2 h intervals. The left anterior
descending (LAD) coronary artery was cannulated and
perfused from the extracorporeal perfusion circuit. Coro-
nary arterial pressure was measured from the sidearm of the
coronary cannula and held above 75 mmHg to avoid
hypoperfusion prior to ischemia by adjusting the roller
pump. Heart rate was controlled by left atrial pacing (Hugo
Sachs Elektronik Type 215/T, Hugstetten, Germany).
Regional myocardial blood flow
Radiolabeled microspheres (15 μm in diameter;
46Sc;
Perkin Elmer, Waltham, MA, USA) were injected into the
coronary perfusion circuit to determine the area at risk and
regional myocardial blood flow (Wizzard 2740, Perkin
Elmer, Waltham, MA, USA). Subendocardial blood flow to
the inner myocardial layers, where most of the infarction
and a potential redistribution of flow occur, is reported.
Infarct size
At the end of each experiment, the heart was sectioned from
base to apex into 5 transverse slices in a plane parallel to
the atrioventricular groove. Slices were immersed in
0.09 mol/L sodium phosphate buffer containing 1.0%
triphenyl tetrazolium chloride (Sigma-Aldrich Chemie
Gmbh, Munich, Germany) and 8% dextran for 20 min at
37°C. The amount of infarcted tissue is expressed as
percent of the area at risk, as defined by microspheres.
Drug administration
Dronedarone (2.5 mg/kg body weight) was dissolved in
15 ml 1:2 saline/PEG400 (Sigma Aldrich, Schnelldorf,
Germany). In preliminary experiments, the i.v. infusion of
dronedarone caused generalized vasodilation, as character-
ized by hypotension and increased coronary blood flow. To
minimize such initial vasodilator effect of dronedarone, the
infusion was then fractionated. During infusion (1 ml/min),
coronary perfusion pressure was held above 75 mmHg.
After injection of 5 ml dronedarone solution, the infusion
was stopped. As soon as coronary blood flow had returned
to baseline and systemic hemodynamics had reached a
steady state, the infusion was continued. The heart rate
reduction by ten beats/minute with our acute i.v. administration
of dronedarone was somewhat more pronounced than that of
four beats/minute with chronic oral administration in the
ATHENA trial [13], but in a similar range. To control for
effects of the solvent per se, 15 ml of 1:2 saline/PEG400 were
given i.v. prior to the start of the protocol in each experiment;
this placebo solution caused no measurable effect.
Experimental protocol
Dronedarone (n=6) After administration of dronedarone,
heart rate and left ventricular pressure were restored back to
baseline values by atrial pacing and aortic constriction,
respectively. Coronary inflow was then reduced to 10% of
baseline and maintained constant. At 5–10 min ischemia, a
198 Cardiovasc Drugs Ther (2011) 25:197–201measurement of regional myocardial blood flow was
performed. After 90 min ischemia the myocardium was
reperfused for 2 h.
Placebo (n=8) The protocol was identical to that of the
dronedarone group, except that the infusion of dronedarone
was replaced by saline.
Statistics
Data are mean±SEM. Hemodynamics were analyzed by
two-way ANOVA for repeated measures. When a signifi-
cant difference was detected, individual mean values were
compared by Fisher’s post-hoc tests (LSD). Area at risk,
infarct size, and subendocardial blood flow during ischemia
were compared by Student’s t-tests. Linear regression
analyses between ischemic subendocardial blood flow in
the area at risk and infarct size were performed separately
for dronedarone and placebo and then compared by
ANCOVA. Differences were considered significant at the
level of p<0.05.
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Fig. 2 Infarct size as a function of subendocardial blood flow during
ischemia. With dronedarone, the relationship is shifted downwards
(ANCOVA), reflecting reduced infarct size for any given residual
blood flow
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Fig. 1 Area at risk, infarct size, and subendocardial blood flow during
ischemia with dronedarone and placebo
Time HR LVPmax dPdtmax CAPmean CBFmean
[1/min] [mmHg] [mmHg/s] [mmHg] [ml/min]
Dronedarone (=6) Baseline 88±8 101±2 1,648±164 132±11 18.9±1.4
PEG 88±8 101±3 1,599±141 135±7 19.9±1.5
Dronedarone 78±4
# 80±4
#* 814±54
#* 110±5 21.9±1.5
Match 91±7 101±2 858±42
#* 132±5 19.4±1.4
Isch5 90±7 81±4* 731±33* 26±3* 2.0±0.1*
Isch85 96±6 92±4 986±57* 34±7* 2.0±0.1*
Rep10 99±6 80±5* 923±103
#* 116±8* 47.0±8.0*
Rep30 104±7* 78±4* 1,007±56
#* 113±7* 35.0±4.9*
Rep60 106±5* 79±3* 1,063±29
#* 114±6* 31.0±4.2
#*
Rep120 110±7* 76±2* 1,155±100* 120±8 27.9±3.4
#*
Placebo (n=8) Baseline 92±3 93±3 1,411±56 121±3 20.8±1.5
PEG 93±1 94±3 1,388±61 124±3 21.5±2.2
Placebo 93±1 92±2 1,376±65 116±4 20.6±2.0
Match 91±2 93±2 1,346±47 118±8 20.8±1.8
Isch5 93±1 77±3* 982±54* 23±2* 2.3±0.3*
Isch85 102±5 83±4* 1,165±88* 34±8* 2.3±0.3*
Rep10 105±7* 80±1* 1,325±118 113±6 40.4±3.5*
Rep30 103±5 80±4* 1,343±178 119±9 39.9±3.6*
Rep60 113±4* 78±3* 1,448±120 108±4 40.7±3.3*
Rep120 113±5* 75±3* 1,309±111 108±6 39.1±3.9*
Table 1 Systemic
hemodynamics
PEG: after i.v. injection of
PEG400; Dronedarone/Placebo:
steady state after complete dro-
nedarone/placebo infusion;
Match: restoration of baseline
values by atrial pacing and
aortic constriction; Isch5/85: 5/
85 min after the onset of ische-
mia; Rep10/30/60/120: 10/30/
60/120 min reperfusion
HR heart rate; LVPmax
maximal left ventricular pres-
sure; dPdtmax maximal rate
of rise of left ventricular pres-
sure; CAPmean mean coronary
arterial pressure; CBFmean
mean coronary blood flow
*p<0.05 vs. Baseline;
#p<0.05
vs. Placebo (two-way ANOVA
and Fisher’s LSD post-hoc tests)
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Ventricular extrasystoles were observed during ischemia/
reperfusion in most pigs, but not different between groups.
Three pigs experienced ventricular fibrillation, two pigs
with dronedarone during the first minutes of reperfusion
and one pig with placebo after the onset of ischemia; in all
cases, ventricular fibrillation was immediately terminated
by DC countershock.
Hemodynamics at baseline were not different between
dronedarone and placebo (Table 1), and the infusion of
saline/PEG400 solvent did not alter systemic hemodynam-
ics. Dronedarone decreased heart rate, left ventricular
pressure, and left ventricular dP/dt. With atrial pacing and
aortic constriction, heart rate and left ventricular pressure
were restored back to baseline and not different from those
with placebo for the remaining protocol. Left ventricular
dP/dt remained lower but was not different from placebo
during ischemia. The area at risk, expressed as percent of
the left ventricle, and subendocardial blood flow during
ischemia were not different between dronedarone and
placebo. Infarct size was 22%±4% of the area at risk with
dronedarone and 34%±3% (p<0.05) with placebo (Fig. 1).
The relationship between subendocardial blood flow and
infarct size was significantly displaced downwards with
dronedarone (Fig. 2), reflecting a direct cardioprotective
action of dronedarone independent of its potential effect on
residual blood flow.
Discussion
In the present study dronedarone reduced myocardial
infarct size (Fig. 1). In our constant flow preparation,
dronedarone did not improve blood flow or its distribu-
tion. The observed infarct size reduction was independent
from residual blood flow during ischemia, as reflected by
the downwards displacement of the flow/infarct size
relationship with dronedarone (Fig. 2). While admittedly
we cannot exclude that atrial pacing or aortic constriction
per se have an effect on infarct size, we used atrial pacing
and aortic constriction to match heart rate and blood
pressure in the dronedarone group to those in the placebo
group and can therefore exclude that the protection by
dronedarone was secondary to heart rate or blood pressure
reduction.
While the present study clearly demonstrates a direct
cardioprotective action of dronedarone in a highly relevant
model of regional myocardial ischemia/reperfusion in pigs,
a species with a similar spatial and temporal development
of infarction as humans, and a high translational value [12,
14], it does not provide a mechanistic explanation for such
cardioprotection. Among the several ion channels which are
inhibited by dronedarone, the inhibition of the sodium-
calcium exchanger [3] might be of particular importance as
this would reduce calcium overload during myocardial
ischemia/reperfusion and thus contribute to the mainte-
nance of viability [15]. Pharmacological inhibition of
sodium-calcium exchange has indeed been shown to
decrease calcium overload and hypercontracture in rat
cardiomyocytes and to reduce infarct size in pigs [16].
However, we currently have no proof for this potential
explanation, and thus the cardioprotective effect of drone-
darone remains “pleiotropic” at this point. We have
previously reported reduced infarct size through a heart
rate-independent, direct cardioprotective, “pleiotropic” ac-
tion of ivabradine, an agent which also acts on ion channels
not only in the sinus node [5, 17, 18]. In fact, dronedarone
also inhibits If channels at a similar potency as ivabradine
[19]. Since, however, we do not know the mechanism
underlying protection by either ivabradine or dronedarone,
we also do not know whether these drugs have a common
mechanism to induce cardioprotection. More reductionist
models may be better suited to identify the mechanistic
background for our observation of direct cardioprotection
[15]. Nevertheless, our present results on dronedarone
support the observation from the ATHENA trial, that
mortality from cardiovascular events is reduced with
dronedarone [4].
Conflict of interest The present study was supported by an
unrestricted educational grant from sanofi-aventis Germany GmbH.
GH has received honoraria for lectures from sanofi-aventis Germany
GmbH.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S,
et al. Guidelines for the management of atrial fibrillation: the task
force for the management of atrial fibrillation of the European
Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.
2. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of
atrial fibrillation. Lancet. 2010;375:1212–23.
3. Watanabe Y, Kimura J. Acute inhibitory effect of dronedarone, a
noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+
exchange current in guinea pig cardiac ventricular myocytes. N
Schmied Arch Pharmacol. 2008;377:371–6.
4. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL,
Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular
events in atrial fibrillation. N Engl J Med. 2009;360:668–78.
5. Heusch G. Heart rate in the pathophysiology of coronary blood
flow and myocardial ischaemia: benefit from selective bradycardic
agents. Br J Pharmacol. 2008;153:1589–601.
200 Cardiovasc Drugs Ther (2011) 25:197–2016. Wichmann J, Ertl G, Hohne W, Schweisfurth H, Wernze H,
Kochsiek K. Alpha-receptor restriction of coronary blood flow
during atrial fibrillation. Am J Cardiol. 1983;52:887–92.
7. Ertl G, Meesmann M, Krumpiegel K, Kocksiek K. The effects of
atrial fibrillation on coronary blood flow and performance of
ischaemic myocardium in dogs with coronary artery stenosis. Clin
Sci. 1987;73:437–44.
8. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess
O, et al. α-Adrenergic coronary vasoconstriction and myocardial
ischemia in humans. Circulation. 2000;101:689–94.
9. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a
new amiodarone-like antiarrhythmic agent: anti-adrenoceptor
activity in anaesthetized and conscious dogs. Eur J Pharmacol.
1995;279:25–32.
10. Finance O, Manning A, Chatelain P. Effects of a new
amiodarone-like agent, SR 33589, in comparison to amiodar-
one, D, L-sotalol, and lignocaine, on ischemia-induced ven-
tricular arrhythmias in anesthetized pigs. J Cardiovasc
Pharmacol. 1995;26:570–6.
11. Hammwöhner M, Bukowska A, Sixdorf A, Röhl F-W, Lendeckel
U, Bode-Böger SM, et al. Dronedaron verhindert Störungen der
koronaren Mikrozirkulation im linken Ventrikel während atrialer
Tachyarrhythmie. Clin Res Cardiol Suppl. 2010;99.
12. Heusch G, Skyschally A, Schulz R. The in-situ pig heart with
regional ischemia/reperfusion- ready for translation. J Mol Cell
Cardiol. 2011. doi:10.1016/j.yjmcc.2011.02.016.
13. Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-
Pedersen C, et al. Rhythm- and Rate-Controlling Effects of
Dronedarone in Patients With Atrial Fibrillation (from the
ATHENA Trial). Am J Cardiol. 2011;107:1019–22.
14. Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM,
Downey J, et al. Translating novel strategies for cardioprotection:
the Hatter Workshop Recommendations. Basic Res Cardiol.
2010;105:677–86.
15. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D,
Hausenloy DJ, et al. Postconditioning and protection from
reperfusion injury: where do we stand? Cardiovasc Res.
2010;87:406–23.
16. Inserte J, Garcia-Dorado A, Ruiz-Meana M, Padilla F, Barrabés
JA, Pina P, et al. Effect of inhibition of Na
+/Ca
2+ exchanger at the
time of myocardial reperfusion on hypercontracture and cell death.
Cardiovasc Res. 2002;55:739–48.
17. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabra-
dine: cardiovascular protection beyond heart rate reduction. Br J
Pharmacol. 2008;155:970–1.
18. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D,
Schulz R. Improvement of regional myocardial blood flow and
function and reduction of infarct size with ivabradine—protection
beyond heart rate reduction. Eur Heart J. 2008;29:2265–75.
19. Bogdan R, Goegelein H, Ruetten H. Effect of dronedarone on
Na
+,C a
2+ and HCN channels. N Schmied Arch Pharmacol.
2011;383:347–56.
Cardiovasc Drugs Ther (2011) 25:197–201 201